

Technologies

6-2018-4612 | Novel Nasal Delivery of Cannabinoid Formulations

[Touitou Elka](#), HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

Keywords	Innovative carrier, Nasal administration, Delivery to brain, Treatment of pain, Parkinson's disease, Multiple Sclerosis, Alzheimer, Epilepsy and brain trauma
Current development stage	Tested in animal model for pain
	Seeking to license the technology

Our innovation

Phospholipid Magnesome carrier has the ability to deliver central acting drugs, peptides, proteins, siRNA and such to brain. It was shown by successful delivery of insulin, oxytocin, EGF and drugs for treating pain, disorders in Parkinson's disease, Multiple Sclerosis, Alzheimer, Epilepsy and brain trauma.

Advantages

- Rapid onset of action - for treatment of Pain, Rigidity in Parkinson's disease.
- Can increase efficiency and patient compliance by avoiding invasive treatments.
- Opens a way for new strategies for treatment of brain and CNS diseases.
- Delivery to Brain Visualized by NIR Imaging and Semi-Quantified





Figure 1 Representative NIR images and semi-quantification of fluorescence intensity in mice brains treated nasally with Epidermal Growth Factor (EGF) IRDye from Phospholipid Magnesome, as compared to water solution (WS), Liposome (Lipo) and nonvesicular system (NV); Mean \pm SD, n=3/ group. Odyssey® Infrared Imaging System, LI-COR, USA

Patent Status

Contact for more information:



Keren-Or Amar
VP, Business Development, Healthcare

Yisum Research Development Company of the Hebrew University of Jerusalem

Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem

P.O. Box 39135, Jerusalem 91390 Israel

Telephone: 972-2-658-6688, Fax: 972-2-658-6689